Cerulean doses first patient in Phase 2 study of small cell lung cancer drug

US based clinical-stage company Cerulean Pharma has dosed the first patient in a randomised Phase 2 study of its anti-cancer drug for treating extensive-stage small cell lung cancer (SCLC).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news